Compare Monster Beverage Corp (MNST) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Monster Beverage Corp trades at $44.82 (market cap $84.85B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Monster Beverage Corp is far larger — about 87.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Monster Beverage Corp is more actively traded (7,847,331 versus 4,325,710). Which is the better fit depends on your goals — on Pluang, investors hold Monster Beverage Corp for 72 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MNST | MRVI | |
|---|---|---|
Market Cap | $84.85B | $972.90M |
Volume | 7,847,331 | 4,325,710 |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $9.00 |
52-Week Low | $33.16 | $2.83 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $83.14B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $44.22, up 1.05% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.30, and maintains robust fundamentals including 55.55% gross margin and 23.08% net margin. Recent news highlights international growth, a debt-free balance sheet, and a 1:2 stock split effective August 2026.
Outlook remains positive with analyst consensus target of $98.22 implying significant upside, supported by international expansion and high profitability. Key risks include valuation multiples above industry averages and regulatory challenges in markets like India. The stock's growth trajectory is solid, but investors should weigh rich valuations against execution risks.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
